Research-Focused Blog Posts
Our blog posts offer concise, expert commentary on the latest developments in VHH technology. From new research findings to industry updates and practical tips, each article is written to inform and support your scientific work.
Solid Tumour Targeting – VHH antibodies as building blocks for advanced cancer therapies
Cancer continues to pose a significant challenge in the realm of biomedical research, particularly with respect to solid tumors, which constitute over 90% of adult cancer cases.But what makes solid tumors so challenging? And what solutions are available to overcome...
Unlocking Affordable Biologics: VHH Antibodies in Baker’s Yeast
The production of traditional IgG monoclonal antibodies has long been hindered by their complexity. These molecules require complex and costly manufacturing processes, with estimated production costs ranging from $95 to $200 per gram. As well as contributing to issues...
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
Challenging assumptions in antigen QC for antibody discovery success
Not all projects go as planned, but breakthroughs often emerge from the most unexpected challenges. This case study explores how a technical obstacle during early QC could have derailed a VHH discovery project - but turned into a demonstration of collaboration,...
Synthetic Biology Technologies for Antibody Discovery
Imagine bypassing the lengthy traditional immunization process and tapping into the antibody diversity equivalent of over a million llamas – right at your fingertips. Synthetic Biology Technologies are transforming antibody discovery, accelerating the design of targeted therapies with greater precision, speed, and reduced risk. Read now!
Nanobody or VHH – What’s the difference?
In the realm of biotechnology and medicine, the terms nanobody and VHH are often used interchangeably to describe single-domain antibodies. These small-format versions of traditional antibodies have grown as cornerstones of scientific innovation from diagnostics to cell and gene therapies. But where do these names come from, and what meanings do they have for describing what makes them so pivotal in today’s research and therapeutic applications?
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles
Isogenica developed a screening approach using pre-engineered C-terminal Cysteine handles. VHHs expressed well in this format and formed spontaneous stable dimers. This approach can now be applied to future projects which require VHH antibody conjugation for ADC and other applications.
Specific Antibodies to Difficult Targets: How to find the needles in the haystack
Peptides, often small and unstructured, are some of the most difficult targets in antibody discovery. Here, we recount how we tweaked our approach to mining our vast VHH libraries to isolate highly specific binders for difficult targets like these, even when other methods had failed.
Advantages of using VHH antibodies for CAR engineering
We explain the advantages of VHHs for CAR ectodomain targeting relative to traditional scFvs including size, solubility, and VHHs unique “magic finger” CDR3 domain.
Small antibodies, big libraries
As VHH antibody experts, we’re big proponents of using synthetic libraries for antibody discovery. But what exactly are the benefits? Do they even produce good molecules? And what do you gain by having access to the largest and most diverse VHH libraries on the market?